Literature DB >> 9716011

Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines.

E Pons1, C C Uphoff, H G Drexler.   

Abstract

Recent studies have shown that hepatocyte growth factor (HGF) is a regulatory protein for the proliferation and differentiation of hematopoietic progenitors. The proto-oncogene c-met encodes a tyrosine kinase receptor that binds HGF. To obtain information about their possible involvement in the pathogenesis of hematopoietic tumors, we have examined the expression of HGF and c-met in a large panel of leukemia-lymphoma cell lines encompassing all major hematopoietic cell lineages. HGF and c-met mRNAs were detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and Northern blotting. The panel of 92 cell lines analyzed comprised seven B-cell precursor, ten B-cell, six plasma cell, 13 T-cell, four natural killer (NK) cell, 16 myelocytic, 12 monocytic, 13 erythroid-megakaryocytic and 11 Hodgkin-anaplastic large cell lymphoma (ALCL) lines. In total 64 (70%) were RT-PCR-positive for HGF and 43 (47%) for c-met. The highest percentages of expression were found for HGF in the plasma cell (100%), NK (100%) and myeloid (75-92%) cell line categories, whereas c-met was found predominantly in plasma cell (100%) and Hodgkin-ALCL (91%) cell lines. The concomitant expression of HGF and c-met in plasma cell lines (100%) and Hodgkin-ALCL (73%) cell lines should be noted. The high HGF expression in myelocytic-monocytic cell lines (75 and 92%) contrasts with the low c-met expression (18 and 8%) in these cell lineages. In 50 cell lines, mRNA expression of these two genes was also examined at the Northern blot level: 12/50 (24%) and 4/48 (8%) were positive for HGF and c-met mRNA expression, respectively. Of note, three of the four c-met + lines belonged to the category Hodgkin-ALCL; the Hodgkin cell line SUP-HD-1 showed both HGF and c-met mRNA bands suggesting the possibility of an autocrine loop. In conclusion, we detected HGF expression in various types of leukemia-lymphoma cell lines, particularly in plasma cell and myeloid malignancies; c-met expression was found in plasma cell and Hodgkin-ALCL cell lines. Further detailed analysis of the role of this ligand-receptor pair in the pathogenesis of hematopoietic neoplasms is indicated; to this end the HGF + and c-met + cell lines described here represent exquisite model systems.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716011     DOI: 10.1016/s0145-2126(98)00071-x

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

Review 1.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 2.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

3.  Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma.

Authors:  Chuanhui Xu; Wouter Plattel; Anke van den Berg; Nele Rüther; Xin Huang; Miao Wang; Debora de Jong; Hans Vos; Gustaaf van Imhoff; Andreas Viardot; Peter Möller; Sibrand Poppema; Arjan Diepstra; Lydia Visser
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

4.  Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.

Authors:  Victoria E Wang; Bradley W Blaser; Ravi K Patel; Gregory K Behbehani; Arjun A Rao; Blythe Durbin-Johnson; Tommy Jiang; Aaron C Logan; Matthew Settles; Gabriel N Mannis; Rebecca Olin; Lloyd E Damon; Thomas G Martin; Peter H Sayre; Karin M Gaensler; Emma McMahon; Michael Flanders; Vivian Weinberg; Chun J Ye; David P Carbone; Pamela N Munster; Gabriela K Fragiadakis; Frank McCormick; Charalambos Andreadis
Journal:  Blood Cancer Discov       Date:  2021-07-16

5.  Overexpression of hepatocyte growth factor protects chronic myeloid leukemia cells from apoptosis induced by etoposide.

Authors:  Xiaojiao Zheng; Shixuan Hua; Hang Zhao; Zhou Gao; Dong Cen
Journal:  Oncol Lett       Date:  2022-02-15       Impact factor: 2.967

6.  Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET.

Authors:  Takayoshi Shirasaki; Satoshi Yamagoe; Tetsuro Shimakami; Kazuhisa Murai; Ryu Imamura; Kiyo-Aki Ishii; Hiroaki Takayama; Yukako Matsumoto; Natsumi Tajima-Shirasaki; Naoto Nagata; Ryogo Shimizu; Souma Yamanaka; Atsushi Abe; Hitoshi Omura; Kazunori Kawaguchi; Hikari Okada; Taro Yamashita; Tomoki Yoshikawa; Kazuhiro Takimoto; Motoko Taharaguchi; Shogo Takatsuka; Yoshitsugu Miyazaki; Toshikatsu Tamai; Yamato Tanabe; Makoto Kurachi; Yasuhiko Yamamoto; Shuichi Kaneko; Kunio Matsumoto; Toshinari Takamura; Masao Honda
Journal:  Nat Commun       Date:  2022-06-08       Impact factor: 17.694

7.  c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.

Authors:  Anna Otte; Finn Rauprich; Juliane von der Ohe; Yuanyuan Yang; Friedrich Kommoss; Friedrich Feuerhake; Peter Hillemanns; Ralf Hass
Journal:  Oncotarget       Date:  2015-10-13

8.  Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.

Authors:  Yuki Uchihara; Fumihito Ueda; Kenji Tago; Yosuke Nakazawa; Tomoyuki Ohe; Tadahiko Mashino; Shigenobu Yokota; Tadashi Kasahara; Hiroomi Tamura; Megumi Funakoshi-Tago
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

9.  Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

Authors:  Cecilia Lezcano; Chung-Wei Lee; Allison R Larson; Alexander M Menzies; Richard F Kefford; John F Thompson; Martin C Mihm; Shuji Ogino; Georgina V Long; Richard A Scolyer; George F Murphy
Journal:  Mod Pathol       Date:  2014-01-17       Impact factor: 7.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.